Gracell Biotechnologies Inc is a biotechnology business based in the US. Gracell Biotechnologies shares (GRCL) are listed on the NASDAQ and all prices are listed in US Dollars. Gracell Biotechnologies employs 202 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Gracell Biotechnologies
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – GRCL – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Gracell Biotechnologies stock price (NASDAQ: GRCL)Use our graph to track the performance of GRCL stocks over time.
Gracell Biotechnologies shares at a glance
|Latest market close||$10.42|
|52-week range||$9.75 - $33.70|
|50-day moving average||$13.24|
|200-day moving average||$12.66|
|Wall St. target price||$34.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.36|
Buy Gracell Biotechnologies shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Gracell Biotechnologies stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Gracell Biotechnologies price performance over time
|1 week (2021-10-18)||-20.21%|
|1 month (2021-09-24)||-23.38%|
|3 months (2021-07-23)||-12.58%|
|6 months (2021-04-23)||-19.10%|
|1 year (2020-10-21)||N/A|
|2 years (2019-10-21)||N/A|
|3 years (2018-10-21)||N/A|
|5 years (2016-10-21)||N/A|
Gracell Biotechnologies financials
|Gross profit TTM||$0|
|Return on assets TTM||-19.46%|
|Return on equity TTM||-39.42%|
|Market capitalisation||$700.7 million|
TTM: trailing 12 months
Shorting Gracell Biotechnologies shares
There are currently 1.1 million Gracell Biotechnologies shares held short by investors – that's known as Gracell Biotechnologies's "short interest". This figure is 3.6% down from 1.1 million last month.
There are a few different ways that this level of interest in shorting Gracell Biotechnologies shares can be evaluated.
Gracell Biotechnologies's "short interest ratio" (SIR)
Gracell Biotechnologies's "short interest ratio" (SIR) is the quantity of Gracell Biotechnologies shares currently shorted divided by the average quantity of Gracell Biotechnologies shares traded daily (recently around 53529.262335125). Gracell Biotechnologies's SIR currently stands at 20.47. In other words for every 100,000 Gracell Biotechnologies shares traded daily on the market, roughly 20470 shares are currently held short.
To gain some more context, you can compare Gracell Biotechnologies's short interest ratio against those of similar companies.
However Gracell Biotechnologies's short interest can also be evaluated against the total number of Gracell Biotechnologies shares, or, against the total number of tradable Gracell Biotechnologies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Gracell Biotechnologies's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Gracell Biotechnologies shares in existence, roughly 20 shares are currently held short) or 0.0274% of the tradable shares (for every 100,000 tradable Gracell Biotechnologies shares, roughly 27 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Gracell Biotechnologies.
Find out more about how you can short Gracell Biotechnologies stock.
Gracell Biotechnologies share dividends
We're not expecting Gracell Biotechnologies to pay a dividend over the next 12 months.
You may also wish to consider:
- Amgen (AMGN.US) (3.22% forward annual dividend yield)
Gracell Biotechnologies overview
Gracell Biotechnologies Inc. , a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise; and GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase I clinical trial for the treatment of r/r B-ALL. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China. .
Gracell Biotechnologies in the news
Humanigen Elects John Hohneker, MD, and Kevin Xie, PhD, to Board of Directors
Gracell Biotechnologies to Participate in Two Upcoming Virtual Investor Conferences
Gracell Biotechnologies : to Participate in Two Upcoming Virtual Investor Conferences
Frequently asked questionsWhat percentage of Gracell Biotechnologies is owned by institutions?
Currently 31.218% of Gracell Biotechnologies shares are held by institutions. How many people work for Gracell Biotechnologies?
Latest data suggests 202 work at Gracell Biotechnologies. When does the fiscal year end for Gracell Biotechnologies?
Gracell Biotechnologies's fiscal year ends in December. Where is Gracell Biotechnologies based?
Gracell Biotechnologies's address is: Building 12, Block B, Suzhou, China, 215123 What is Gracell Biotechnologies's ISIN number?
Gracell Biotechnologies's international securities identification number is: US38406L1035
More guides on Finder
How to buy ProShares Bitcoin Strategy ETF (BITO)
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
How to buy The Real Good Food Company (RGF) stock when it goes public
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
How to buy Lulu’s Fashion Lounge Holdings (LVLU) stock when it goes public
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
How to buy Allarity Therapeutics (ALLR) stock when it goes public
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
How to buy Jupiter Neurosciences (JUNS) stock when it goes public
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
How to buy Mainz Biomed (MYNZ) stock when it goes public
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
How to buy Progressive Care stock when it goes public
Everything we know about the Progressive Care IPO, plus information on how to buy in.
How to buy Desert Peak Minerals (DPM) stock when it goes public
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
How to buy Vaxxinity (VAXX) stock when it goes public
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
How to buy Entrada Therapeutics (TRDA) stock when it goes public
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
Ask an Expert